Schreiner MediPharm Developed New GLP-1 Security Label
The firm introduced a multifunctional label featuring anti-counterfeiting technology for drug pens and autoinjectors.
Updated on Sept. 24, 2026 in Diabetes
Live Poll
Do you trust pharmaceutical companies to successfully use new technology to prevent drug counterfeiting?
Schreiner MediPharm has released a new, specialized label designed for GLP-1 drug pens and autoinjectors. The label incorporates both analog and digital security features to combat the rise of counterfeit medications.
Why it matters
The high global demand for GLP-1 drugs, used to treat diabetes and obesity, has turned these medical products into frequent targets for counterfeiters. This technology aims to protect patient safety by verifying the authenticity of the medication.
The label integrates ShiftSecure visual effects that change based on viewing angle, along with InfraredSecure and microtext. It also features smartphone-readable NFC chips to facilitate digital authentication and user support.
The players
Schreiner MediPharm
This company is a specialized manufacturer of labeling and packaging solutions for the pharmaceutical and medical device industries.
The details
The design includes a tamper-detection mechanism that leaves printed residue behind if the label is removed from the device. Additionally, the label covers the pen cap to prevent unauthorized recapping and provides an extended area for essential product information.
Timeline
The new label technology was officially announced on September 24, 2026.
Deeper Dive
This development complements the global regulatory standards established by the serialization requirements of the Drug Supply Chain Security Act. It represents a shift toward more robust, multi-layered security protocols within the global pharmaceutical supply chain.
Patients can use their smartphones to scan NFC chips on the device labels to confirm the authenticity of their medication. This technology ensures that users can verify they are receiving genuine treatment rather than potentially dangerous counterfeit products.
The takeaway
Counterfeit medical devices pose significant health risks to patients relying on regular dosages of GLP-1 treatments. Consumers should always check for integrated security markers and use official authentication tools provided by manufacturers when available.
Further reading
Learn more about the latest innovations in Diabetes care and management technologies.
Source note: This article includes information reported by Labelsandlabeling.
Live Poll
Do you trust pharmaceutical companies to successfully use new technology to prevent drug counterfeiting?
